OFI Invest Asset Management Invests $945,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

OFI Invest Asset Management purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 5,300 shares of the medical research company’s stock, valued at approximately $945,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in CRL. Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after buying an additional 3,738,018 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Charles River Laboratories International during the 4th quarter worth $42,776,000. Mizuho Securities USA LLC grew its position in shares of Charles River Laboratories International by 2,336.4% during the 3rd quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after buying an additional 92,895 shares in the last quarter. Premier Fund Managers Ltd grew its position in shares of Charles River Laboratories International by 56.3% during the 3rd quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock worth $49,573,000 after buying an additional 90,000 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after buying an additional 85,759 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 4.1 %

Shares of NYSE:CRL opened at $176.20 on Monday. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $274.77. The stock has a market cap of $9.01 billion, a price-to-earnings ratio of 1,174.68, a PEG ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $169.15 and a 200-day moving average price of $185.63.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the business posted $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CRL shares. Robert W. Baird dropped their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. TD Cowen raised their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Morgan Stanley dropped their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. Finally, The Goldman Sachs Group dropped their price objective on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $198.36.

Insider Transactions at Charles River Laboratories International

In related news, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).